Komori
Daiken Medical (7775) · InitiativeRestated

Production System Balancing Quality and Cost Competitiveness

First written in FY2017-Q1. 25 of 27 entries say "Restated". Latest entry: 2026-07-31.

27entries
11years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017-Q1 – FY2026-H12016: 220162017: 420172018: 420182019: 220192020: 220202021: 220212022: 220222023: 320232024: 220242025: 220252026: 22026
Same theme, other companies
Transition to a high-quality, low-cost operating structureA theme 29 companies write about · 1 as a headwind · 28 as a tailwind

The whole theme swung hardest in 2026: 6 of 21 companies on the "Worse" side.

13 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 29 companies compared. The sentences above are computed from all 29.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1RestatedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The Company continues to build a production system that balances quality assurance and cost competitiveness.
  2. FY2025RestatedAnnual report

    「Since fiscal 2024, we have been using data on production, inventory and logistics to optimize production activities and improve production efficiency and reduce costs.」

    The company continues to pursue a production system that combines quality with cost competitiveness, citing production, inventory and logistics data, shorter lead times, inventory optimization, multiple-source procurement, restructuring of the production system, and improved processing yields as specific measures.
  3. FY2025-H1RestatedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The Company continues to build a production system that balances quality assurance and cost competitiveness.
  4. FY2024-Q3RestatedAnnual report

    「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with medical professionals, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」

    The Company continues to build a production system that balances quality assurance and cost competitiveness.
  5. FY2024-Q2RestatedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The Company continues to build a production system that balances quality assurance and cost competitiveness.
  6. FY2024-Q1RestatedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The Company continues to build a production system that balances quality assurance and cost competitiveness.
  7. FY2023-Q3RestatedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The Company continues to build a production system that balances quality assurance and cost competitiveness.
  8. FY2023-Q2RestatedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The Company continues to build a production system that balances quality assurance and cost competitiveness.
  9. FY2022RestatedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The company continues to pursue a policy of combining quality with cost competitiveness, citing design changes to streamline components and labor hours, labor-saving improvements to production equipment, and supply chain optimization as specific measures.
  10. FY2022-Q1RestatedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The Company continues to build a production system that balances quality assurance and cost competitiveness.
  11. FY2021RestatedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The Company continues to build a production system that balances quality assurance and cost competitiveness.
  12. FY2020RestatedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The Company continues to build a production system that balances quality assurance and cost competitiveness.
  13. FY2020-Q3RestatedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The Company continues to build a production system that balances quality assurance and cost competitiveness.
  14. FY2019RestatedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The Company continues to build a production system that balances quality assurance and cost competitiveness.
  15. FY2019-Q3RestatedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The Company continues to build a production system that balances quality assurance and cost competitiveness.
  16. FY2019-Q2RestatedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The company continues to pursue the establishment of a production system that combines quality assurance with cost competitiveness.
  17. FY2019-Q1RestatedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The company continues to pursue the establishment of a production system that combines quality assurance with cost competitiveness.
  18. FY2018RestatedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The company continues to pursue the establishment of a production system that combines quality assurance with cost competitiveness.
  19. FY2018-Q3RestatedAnnual report

    「Against this backdrop, the Company made the consistent, stable supply of high-quality products a priority and worked to strengthen sales activities closely aligned with users, establish a cost-competitive production system while maintaining quality, and reinforce research and development of original products.」

    The company continues to establish a production system that combines quality assurance with cost competitiveness.
  20. FY2018-Q2RestatedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The Company continues to build a production system that balances quality assurance and cost competitiveness.
  21. FY2018-Q1RestatedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The Company continues to build a production system that balances quality assurance and cost competitiveness.
  22. FY2017RestatedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The company continues to pursue the establishment of a production system that combines quality assurance with cost competitiveness.
  23. FY2017-Q3RestatedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The Company continues to build a production system that balances quality assurance and cost competitiveness.
  24. FY2017-Q2RestatedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The Company continues to build a production system that balances quality assurance and cost competitiveness.
  25. FY2017-Q1First statedAnnual report

    「Building a production system that ensures quality while maintaining cost competitiveness」

    The Company is working to build a production system that maintains quality while ensuring cost competitiveness.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Daiken Medical's next results are scheduled for 2026-10-30. Read the earnings preview It last moved in the Earnings of 2026-07-31: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Production System Balancing Quality and Cost Competitiveness | DAIKEN MEDICAL CO.,LTD. (7775) | Komori